SPARC-deficient mice have been shown to exhibit impaired glucose tolerance and insulin secretion, but the underlying mechanism remains unknown. Here, we show that SPARC enhanced the promoting effect of Muscarinic receptor agonist oxotremorine-M on insulin secretion in cultured mouse islets. Overexpression of SPARC down-regulated RGS4, a negative regulator of β -cell M3 muscarinic receptors. Conversely, knockdown of SPARC up-regulated RGS4 in Min6 cells. RGS4 was up-regulated in islets from sparc -/-mice, which correlated with decreased glucose-stimulated insulin secretion (GSIS). Furthermore, inhibition of RGS4 restored GSIS in sparc -/-mice, and knockdown of RGS4 partially decreased the promoting effect of SPARC on oxotremorine-M stimulated insulin secretion. Phosphoinositide 3-kinase (PI3K) inhibitor LY-294002 abolished SPARC-induced down-regulation of RGS4. Taken together, our data revealed that SPARC promoted GSIS by inhibiting RGS4 in pancreatic β cells. Short running title: SPARC regulates insulin secretion through RGS4
Introduction:
The etiology of Diabetes involves both insulin resistance and decreased insulin secretion in β-cells 1-3 . Adipose tissue inflammation plays an important role in the development of obesity-induced insulin resistance 2, 4 .
In the prediabetic insulin-resistant state, islets respond to the increased insulin demand by increasing insulin secretion and β-cell mass, which generates compensatory hyperinsulinemia and maintains relative normal glycaemia. When insulin secretion is insufficient to compensate for the insulin resistance, type 2 diabetes emerges. The early β cell dysfunction is manifested as impaired glucose-stimulated insulin secretion (GSIS), and loss of first phase GSIS can be detected in the earliest stages of type 2 diabetes 1, 3 .
SPARC (Secreted Protein Acidic and Rich in Cysteine) is expressed mainly in bone and adipocytes, and it is a secreted extracellular matrix protein that is produced as a 32-kDa matricellular glycoprotein [5] [6] [7] [8] [9] . SPARC mediates interactions between cells and their extracellular matrix, and targeted deletion of sparc results in compromised extracellular matrix in mice 7, 10 . SPARC can bind to integrin beta3 and activate integrin linked kinase 11 . Secretion of SPARC by adipose tissue is increased by insulin and leptin 12, 13 . Adipose tissue is a major source of SPARC, which in turn inhibits adipogenesis and induces insulin resistance in adipose tissue in an autocrine or paracrine fashion [14] [15] [16] . SPARC has been shown to be involved in oxidative stress, neurogenesis, insulin resistance, glucose metabolism and Glut4 expression [16] [17] [18] [19] [20] .
SPARC is expressed in the stromal cells of mouse primary islets that can be detected by Western blot, and plays a role in reducing IGF-1-induced islet survival 21 .
sparc-/-mice on high-fat diet showed an impaired insulin secretion capacity and a dramatically reduced expression of glucose transporter 2 in the islets 22 .
SPARC-deficient mice exhibited impaired glucose tolerance 22, 23 , and one of the underlying mechanism is reduced insulin secretion 22 .
Acetylcholine, which is released from intrapancreatic nerve endings, stimulates insulin secretion through binding and activation of M3 muscarinic receptor, resulting in increased intracellular calcium concentration in beta-cells during food ingestion 24 .
Mice selectively lacking M3 muscarinic receptor in pancreatic β-cells displayed impaired glucose tolerance and a dramatic reduction in insulin secretion, demonstrating that M3 muscarinic receptor in β-cells is essential for maintaining normal glucose homeostasis 24 25 . RGS4 is a negative regulator of G protein-coupled M3-muscarinic receptor. Pancreatic beta cell-specific knockout of Rgs4 did not alter basal glucose levels, but increased plasma insulin levels and muscarinic agonist-stimulated insulin release 26 , suggesting that selectively enhancing the M3 muscarinic receptor signaling in pancreatic β-cells could lead to novel treatment for patients with type 2 diabetes 26 .
To elucidate the mechanism by which SPARC regulates insulin secretion and β cell physiology, we had analyzed insulin secretion in SPARC-deficient β cells. Our results demonstrate that SPARC was essential for normal β cell function and promotes insulin secretion by inhibiting RGS4 expression.
Materials and Methods.

Materials.
Sparc -/-mice were a gift from Dr. Neveen Said at University of Virginia, Charlottesville, Virginia, USA 27 and were maintained in the accredited pathogen-free Second Xiangya hospital mice facility on a 12 h light/dark cycle 28 . C57BL/6 mice were purchased from Model Animal Research Center of Nanjing University. All experiments and methods were performed following approval of the protocols by the Animal Care Research Committee of Second Xiangya Hospital. All methods were performed in accordance with the relevant guidelines and regulations.
Human sparc cDNA clone was described by us before 29 and subcloned into pShuttle vector (Clontech). Adenovirus expressing human SPARC was constructed using
Adeno-X expression system (Clontech) as described before 30, 31 
Methods.
Cell Culture. Min6 cells were originally purchased from ATCC and were cultured in DMEM containing 15 % FBS, 25 mM Glucose and 50 uM β-mercaptoethanol as described before 31 . Min6 cells were seeded in a six-well plate and allowed to attach overnight. Min6 cells were incubated for 24 h before collection and analysis.
Islet isolation. Islets were isolated from 8 to 12 weeks old C57BL/6 male mice as described before by our laboratory [31] [32] [33] [34] . Briefly, mouse islets were isolated using perfusion and digestion of pancreas with collagenase V (from Roche), density gradient purification with histopaque-1077 (Sigma), and then hand-picked. Western blots. Western blots were performed using equal amounts of whole cell extract protein as describe before 33, 35 . Briefly, cell lysates were run on SDS PAGE, proteins transferred to a nitrocellulose membrane. The membranes were incubated with the primary antibodies, rabbit anti-RGS4 (Santa cruz), mouse anti-SPARC (Haematologic Technologies, Inc), rabbit anti-AKT-S473, rabbit anti-AKT, mouse anti-beta-actin (Cell Signaling), respectively, followed by Horseradish peroxidase labeled donkey anti rabbit or donkey anti mouse antibodies. Protein signal was visualized by using Immun-Star chemiluminescent kit (Bio-Rad) and quantified by Bio-Rad Imager.
Adenoviral infection.
Adenovirus was amplified in 293 HEK cells. The adenovirus in 293 cells was collected and subjected to three cycles of freeze-thaw.
Adenovirus titer was determined by using Adeno-X rapid titer kit from Clontech.
Min6 cells or isolated islets were infected with Ad-SPARC or Ad-EGFP at 100 MOI for 16 hours. The next day, the medium was changed and the cells were cultured for total 48 hours. We used Ad-GFP virus as control and the expression of GFP inside the core of islets was confirmed under fluorescent microscope. Statistics. Statistical significance was assessed by two-tailed Student t test. For multiple groups, statistical significance was performed with one way or two way ANOVA followed by Tukey's multiple comparisons test by GraphPad Prism 7. A value of P <0.05 was considered significance. All data are expressed as the mean +/-
SE.
Results:
SPARC enhances insulin secretion in mouse pancreatic β-cells
To determine the effect of SPARC on insulin secretion, we overexpressed SPARC by adenovirus in isolated mouse islets. SPARC overexpression enhanced muscarinic receptor agonist Oxotremorine M-stimulated insulin secretion ( Fig. 1A) . To confirm this effect, we also treated cells with recombinant SPARC protein. As shown in Fig. 1B, SPARC enhanced Oxotremorine M-stimulated insulin secretion in mouse islets.
Downregulation of RGS4 by Overexpression of SPARC
To study the changes of gene expression induced by overexpression of SPARC, we conducted cDNA microarray in Min6 cells overexpressing SPARC using Affimetrix mouse cDNA chip and found down-regulation by SPARC of RGS-4 mRNA to 0.38-fold compared to Ad-EGFP-infected Min6 cells ( Fig. 2A) ; SPARC also induced MafA, Glut2, Notch2 and NeuroD2 by >2-folds as shown in Fig. 2A .
Since RGS4 is a known negative regulator of insulin secretion through inhibition of muscarinic M3 receptor-G(q) protein coupling in β cells, we further investigated the effect of SPARC overexpression and loss of sparc on RGS4 expression. To confirm the microarray data, we overexpressed SPARC and analyzed RGS4 mRNA levels by RT-qPCR. As shown in Fig 
Up-regulated RGS4 protein in pancreatic islets in sparc -/-mice
We reasoned that if SPARC inhibits RGS4 expression, knockdown of SPARC would increase RGS4 expression. As shown in Fig. 3A , treatment with siRNA against sparc gene transcripts reduced SPARC expression by 60% in Min6 cells ( Fig. 3 A) and the reduction of SPARC resulted in the increase in RGS4 expression by 2.5-fold ( Fig. 3A, B ).
To further corroborate the siRNA result in Fig. 3A and B, we also examined the effect of loss of sparc gene on expression of RGS4 protein in the islet of sparc -/-mice.
We isolated islets from wild type (WT) and sparc -/-mice, performed Western blot analysis of RGS4 on these islets, and found that RGS4 protein levels were also up-regulated in the islets of sparc -/-mice ( Fig. 3C, D) .
SPARC down-regulates RGS4 partially through activating Phosphoinositide
3-kinase and AKT signaling pathway
Since PI3K/Akt/GSK3beta pathway reduces IL-1beta-induced upregulation of RGS4 expression by inhibiting NF-kappaB activation 36 protein levels in Min6 cells (Fig. 4E, F) . Furthermore, LY-294002 abolished the induction of AKT 473 phosphorylation and down-regulation of RGS4 protein by SPARC ( Fig. 4E, F) . Meanwhile, the changes of total AKT protein levels were not significant in either treatment. The data suggest that the activation of PI3K by SPARC played a role in the down-regulation of RGS4 expression. Taken together, these results indicated that in Min6 cells, SPARC down-regulated RGS4 expression levels at least partially through activating PI3K signaling pathway.
Impaired insulin secretion in isolated islets of sparc -/-mice
To directly assess effect of SPARC on β-cell function, we carried out in vitro culture systems on isolated islets. First, to directly test the function of SPARC in β-cells,
we measured insulin secretion under static incubation conditions by isolated islets obtained from WT and sparc -/-mice. As seen in Fig. 5A , the islets isolated from sparc -/-mice demonstrated significantly lower insulin secretion compared to those of WT mice in response to both high glucose and Oxo-M stimulation. Taken together, these data indicated that SPARC was necessary for normal insulin secretory function in response to glucose and Oxo-M in vitro in mouse β-cells.
Inhibition of RGS4 in cultured islets from sparc -/-mice restores Oxo-M stimulated GSIS
To demonstrate that increased RGS4 in sparc -/-mice is directly linked to impaired GSIS, we inhibited RGS4 function by administering CCG4986, a specific RGS4 inhibitor, in cultured islets isolated from sparc -/-mice. In islets of sparc -/-mice, both 16.7 mM high glucose and high glucose plus Oxo-M agonist did not induce GSIS (Fig. 5A ). However, RGS4 inhibitor CCG-4986 restored high glucose and
Oxo-M-induced GSIS (Fig. 5B ). CCG-4986 increased insulin secretion by 3-fold, compared with control DMSO under high glucose plus Oxo-M condition.
Furthermore, in order to confirm that SPARC regulates insulin secretion principally through RGS4, we used siRNA against rgs4 gene transcripts to knockdown RGS4 expression. As shown in Fig. 5C , treatment with siRNA reduced RGS4 expression by 80% in Min6 cells ( Fig. 5 C) , and knockdown of RGS4 partially decreased the promoting effect of SPARC on oxotremorine-M stimulated insulin secretion (Fig. 5D ).
Taken together, these results suggested a potential pathway by which SPARC regulated insulin secretion through RGS4 (Fig. 5E ).
Discussion.
In this study, we found that overexpression of SPARC inhibited RGS4 expression in Min6 cells; conversely, absence of SPARC increased RGS4 expression in the islets of sparc -/-mice. SPARC overexpression or exogenously administered recombinant SPARC increased muscarinic receptor agonist-stimulated insulin secretion. Here, we describe a novel mechanism for regulating β-cell function through SPARC-RGS4 pathway (Fig. 5E ). The impaired insulin secretion represents a primary β-cell defect because isolated islets from sparc mice exhibited impaired GSIS compared to WT islets.
Previous study showed that SPARC increases human islet insulin secretion 37 . Stable SPARC-expressing rat INS cell line also increases high glucose stimulated insulin secretion, but the mechanism was not elucidated 37 . Our study in Min6 cell line and in isolated mouse islets showed that SPARC increased muscarinic receptor agonist-stimulated insulin secretion, suggesting that one of the mechanisms by which SPARC increases insulin secretion may be through suppression of RGS4 expression.
RGS4 is one of seven members of the classic R4 RGS protein family that accelerates the intrinsic GTPase activity of Gαi/o and Gαq/11 family members. RGS4 inhibits the strength and duration of Gq signaling. In β-cells, RGS4 has been shown to negatively regulate insulin secretion through regulation of M3 receptor-G protein coupling 26 .
During meals, acetylcholine is released from intra-pancreas parasympathetic nerve endings and bound to M3 receptors in β-cells, resulting in activation of PLCγ, IP3 and calcium release, and insulin secretion. We showed that increased SPARC expression inhibited RGS4 expression, which in turn would result in increased M3 receptor G-protein coupling and increased insulin secretion (Fig. 5E ).
Our results are consistent with a recent study demonstrating that SPARC is necessary for insulin secretion in mouse β cells and that sparc -/-mice displayed glucose intolerance and diabetes in an age-dependent manner 22 . Moreover, Glucose transporter 2 (Glut2) expression in β cells is also reduced in sparc -/-mice 22 , which is in agreement with our cDNA microarray data showing induction of Glut2 by SPARC in Min6 cells ( Fig. 2A) . In mouse β cells, receptor-activated Gq leads to the sequential activation of ERK1/2 and IRS2 signaling and selective increases in the expression of islet genes involved in insulin synthesis (Ins2, Pcks1, and Pcks2), and Glut2, thus improving β cell function 38 . In Rat INS1-M3 insulinoma cell line, M3
receptor-mediated activation of Gq leads to increased Irs2 expression via sequential activation of PLC (PLCβ), PKC, and ERK1/2 38, 39 .
PI3K activation inhibits RGS4 mRNA and protein in rabbit colonic smooth muscle cells, which was reversed by PI3K inhibitor LY-294002 36, 40 . We hypothesized that SPARC down-regulates RGS-4 expression through PI3K activation. Treatment of Min6 cells with LY-294002 blocked SPARC-induced down-regulation of RGS4 protein (Fig. 4E) , demonstrating that PI3K pathway regulated RGS4 downregulation induced by SPARC in Min6 cells. Our study showed that SPARC increased AKT phosphorylation in Min6 cells (Fig. 4A) , which is downstream of PI3K. Akt phosphorylation has also contributed to increased insulin secretion 41 . SPARC also activates the PI3K/AKT pathway to promote proliferation and metastasis in oral squamous cell carcinoma 42 , suggesting this pathway to be ubiquitous.
Our study suggested that it may be possible to use RGS4 inhibitors to increase insulin secretion. There are several RGS4 inhibitors that would be of interest to test if they can be used to increase insulin secretion. CCG-4986 inhibits RGS4 function through the covalent modification of two spatially distinct cysteine residues on RGS4 43 . Our in vitro GSIS experiments showed that CCG-4986 restored GSIS in the isolated islets of sparc -/-mice, suggesting that the potential mechanism of defective insulin secretion was due to upregulated RGS4.
RGS4 dysfunction has been linked to many diseases, including hypertension, schizophrenia, and Parkinson's disease [44] [45] [46] . RGS4 is induced by IL-1β through activation of NF-κB, and RGS4 induction can in turn cause β-cell dysfunction by inhibiting insulin secretory machinery as exemplified before 36 . Our results suggested that increased RGS4 expression in sparc -/-β-cells was mechanistically linked to a more chronic state of β-cell dysfunction. Since blood SPARC and insulin levels are increased in obesity and early type 2 diabetes 47 , our results also suggested the involvement of SPARC in islet adaptation to insulin resistance in humans by increasing muscarinic receptor-mediated insulin secretion. However, whether SPARC also downregulates RGS4 expression in human β-cells remains to be confirmed.
In conclusion, we had identified a novel mechanism for SPARC to regulate insulin secretion by down-regulation of RGS4 expression and showed that SPARC played a role in the physiology of insulin secretion and in G-protein signaling in β-cells. In the future, it will be interesting to learn whether SPARC can improve insulin secretion in patients with type 2 diabetes through RGS4 pathway. 
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